Macrophage polarization: An opportunity for improved outcomes in biomaterials and regenerative medicine

Biomaterials

Volumn 33, Issue 15, 2012, Pages 3792-3802

  Brown, Bryan N ^a,b   Ratner, Buddy D ^c,d   Goodman, Stuart B ^e,f   Amar, Salomon ^g   Badylak, Stephen F ^a,b,h  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b University of Pittsburgh   (United States)

^c University of Washington   (United States)

^d University of Washington   (United States)

^e STANFORD UNIVERSITY   (United States)

^f Stanford University   (United States)

^g BOSTON UNIVERSITY   (United States)

^h UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Biocompatibility; Foreign body response; Leukocyte; Macrophage

Indexed keywords

CONTEXT DEPENDENT; DEVICE FUNCTIONALITY; DISEASE PROCESS; FOREIGN BODY REACTIONS; FOREIGN BODY RESPONSE; HOST RESPONSE; IMMUNE CELLS; IMPLANTED MATERIALS; LEUKOCYTE; REGENERATIVE MEDICINE; SCAR TISSUES; TISSUE FORMATION; TISSUE REMODELING;

BIOCOMPATIBILITY; POLARIZATION; TISSUE;

MACROPHAGES;

BIOMATERIAL; COLONY STIMULATING FACTOR 1; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADAPTIVE IMMUNITY; ARTICLE; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; EXTRACELLULAR MATRIX; FIBROSIS; HEMOSTASIS; HUMAN; IMMUNE RESPONSE; IMPLANTATION; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; MACROPHAGE; NEOPLASM; NONHUMAN; OBESITY; PATHOGENESIS; PERIODONTAL DISEASE; PHENOTYPIC PLASTICITY; POLARIZATION; PRIORITY JOURNAL; REGENERATIVE MEDICINE; SCAR; SKIN; TISSUE INJURY; WOUND HEALING;

ANIMALS; BIOCOMPATIBLE MATERIALS; CELL POLARITY; HUMANS; MACROPHAGES; PROSTHESES AND IMPLANTS; REGENERATIVE MEDICINE; TREATMENT OUTCOME;

EID: 84858280061     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.02.034     Document Type: Article

References (157)

1. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005, 5:953-964.
2. Shepard J.L., Zon L.I. Developmental derivation of embryonic and adult macrophages. Curr Opin Hematol 2000, 7:3-8.
3. Passlick B., Flieger D., Ziegler-Heitbrock H.W. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 1989, 74:2527-2534.
4. Grage-Griebenow E., Flad H.D., Ernst M. Heterogeneity of human peripheral blood monocyte subsets. J Leukoc Biol 2001, 69:11-20.
5. Sunderkotter C., Nikolic T., Dillon M.J., Van Rooijen N., Stehling M., Drevets D.A., et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 2004, 172:4410-4417.
6. Smith P.D., Ochsenbauer-Jambor C., Smythies L.E. Intestinal macrophages: unique effector cells of the innate immune system. Immunol Rev 2005, 206:149-159.
7. Smythies L.E., Sellers M., Clements R.H., Mosteller-Barnum M., Meng G., Benjamin W.H., et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 2005, 115:66-75.
8. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677-686.
9. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555.
10. Mills C.D., Kincaid K., Alt J.M., Heilman M.J., Hill A.M. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000, 164:6166-6173.
11. Mosser D.M. The many faces of macrophage activation. J Leukoc Biol 2003, 73:209-212.
12. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969.
13. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35.
14. Stout R.D., Watkins S.K., Suttles J. Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages. J Leukoc Biol 2009, 86:1105-1109.
15. Porcheray F., Viaud S., Rimaniol A.C., Leone C., Samah B., Dereuddre-Bosquet N., et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol 2005, 142:481-489.
16. Stout R.D., Jiang C., Matta B., Tietzel I., Watkins S.K., Suttles J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 2005, 175:342-349.
17. Biswas S.K., Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 2009, 30:475-487.
18. Foster S.L., Hargreaves D.C., Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007, 447:972-978.
19. Lawrence T., Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 2011, 11:750-761.
20. Rosenbauer F., Tenen D.G. Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol 2007, 7:105-117.
21. Olson M.C., Scott E.W., Hack A.A., Su G.H., Tenen D.G., Singh H., et al. PU. 1 is not essential for early myeloid gene expression but is required for terminal myeloid differentiation. Immunity 1995, 3:703-714.
22. Nerlov C., Graf T. PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. Genes Dev 1998, 12:2403-2412.
23. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
24. Ruffell D., Mourkioti F., Gambardella A., Kirstetter P., Lopez R.G., Rosenthal N., et al. A CREB-C/EBPbeta cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. Proc Natl Acad Sci USA 2009, 106:17475-17480.
25. Satoh T., Takeuchi O., Vandenbon A., Yasuda K., Tanaka Y., Kumagai Y., et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol 2010, 11:936-944.
26. Takeda K., Tanaka T., Shi W., Matsumoto M., Minami M., Kashiwamura S., et al. Essential role of Stat6 in IL-4 signalling. Nature 1996, 380:627-630.
27. Ohmori Y., Hamilton T.A. IL-4-induced STAT6 suppresses IFN-gamma-stimulated STAT1-dependent transcription in mouse macrophages. J Immunol 1997, 159:5474-5482.
28. Bouhlel M.A., Derudas B., Rigamonti E., Dievart R., Brozek J., Haulon S., et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007, 6:137-143.
29. Odegaard J.I., Ricardo-Gonzalez R.R., Goforth M.H., Morel C.R., Subramanian V., Mukundan L., et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.
30. Savitsky D., Tamura T., Yanai H., Taniguchi T. Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol Immunother 2010, 59:489-510.
31. Nathan C., Ding A. Nonresolving inflammation. Cell 2010, 140:871-882.
32. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011, 11:723-737.
33. Pollard J.W. Trophic macrophages in development and disease. Nat Rev Immunol 2009, 9:259-270.
34. Balkwill F., Charles K.A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211-217.
35. Mantovani A., Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010, 22:231-237.
36. Sica A., Larghi P., Mancino A., Rubino L., Porta C., Totaro M.G., et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008, 18:349-355.
37. Porta C., Riboldi E., Sica A. Mechanisms linking pathogens-associated inflammation and cancer. Cancer Lett 2011, 305:250-262.
38. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
39. Porta C., Subhra Kumar B., Larghi P., Rubino L., Mancino A., Sica A. Tumor promotion by tumor-associated macrophages. Adv Exp Med Biol 2007, 604:67-86.
40. Lin E.Y., Li J.F., Gnatovskiy L., Deng Y., Zhu L., Grzesik D.A., et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006, 66:11238-11246.
41. Lin E.Y., Pollard J.W. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res 2007, 67:5064-5066.
42. Imtiyaz H.Z., Williams E.P., Hickey M.M., Patel S.A., Durham A.C., Yuan L.J., et al. Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest 2010, 120:2699-2714.
43. Steidl C., Lee T., Shah S.P., Farinha P., Han G., Nayar T., et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010, 362:875-885.
44. Ahn G.O., Tseng D., Liao C.H., Dorie M.J., Czechowicz A., Brown J.M. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci USA 2010, 107:8363-8368.
45. Johnson J.L., Newby A.C. Macrophage heterogeneity in atherosclerotic plaques. Curr Opin Lipidol 2009, 20:370-378.
46. Moore K.J., Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011, 145:341-355.
47. Mantovani A., Garlanda C., Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol 2009, 29:1419-1423.
48. Woollard K.J., Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 2010, 7:77-86.
49. Galkina E., Ley K. Leukocyte influx in atherosclerosis. Curr Drug Targets 2007, 8:1239-1248.
50. Ley K., Laudanna C., Cybulsky M.I., Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007, 7:678-689.
51. Boring L., Gosling J., Cleary M., Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998, 394:894-897.
52. Tacke F., Alvarez D., Kaplan T.J., Jakubzick C., Spanbroek R., Llodra J., et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007, 117:185-194.
53. Matthijsen R.A., de Winther M.P., Kuipers D., van der Made I., Weber C., Herias M.V., et al. Macrophage-specific expression of mannose-binding lectin controls atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2009, 119:2188-2195.
54. Gupta S., Pablo A.M., Jiang X., Wang N., Tall A.R., Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997, 99:2752-2761.
55. Galkina E., Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol 2009, 27:165-197.
56. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005, 85:1-31.
57. Llodra J., Angeli V., Liu J., Trogan E., Fisher E.A., Randolph G.J. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci USA 2004, 101:11779-11784.
58. Ylitalo R., Oksala O., Yla-Herttuala S., Ylitalo P. Effects of clodronate (dichloromethylene bisphosphonate) on the development of experimental atherosclerosis in rabbits. J Lab Clin Med 1994, 123:769-776.
59. Stoneman V., Braganza D., Figg N., Mercer J., Lang R., Goddard M., et al. Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. Circ Res 2007, 100:884-893.
60. Boyle J.J., Weissberg P.L., Bennett M.R. Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler Thromb Vasc Biol 2003, 23:1553-1558.
61. Chen A., Mumick S., Zhang C., Lamb J., Dai H., Weingarth D., et al. Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obes Res 2005, 13:1311-1320.
62. Weisberg S.P., Hunter D., Huber R., Lemieux J., Slaymaker S., Vaddi K., et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006, 116:115-124.
63. Olefsky J.M., Glass C.K. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010, 72:219-246.
64. Odegaard J.I., Chawla A. Alternative macrophage activation and metabolism. Annu Rev Pathol 2011, 6:275-297.
65. Pascual G., Ricote M., Hevener A.L. Macrophage peroxisome proliferator activated receptor gamma as a therapeutic target to combat Type 2 diabetes. Expert Opin Ther Targets 2007, 11:1503-1520.
66. Hevener A.L., Olefsky J.M., Reichart D., Nguyen M.T., Bandyopadyhay G., Leung H.Y., et al. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest 2007, 117:1658-1669.
67. Norris A.W., Chen L., Fisher S.J., Szanto I., Ristow M., Jozsi A.C., et al. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 2003, 112:608-618.
68. Wu D., Molofsky A.B., Liang H.E., Ricardo-Gonzalez R.R., Jouihan H.A., Bando J.K., et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 2011, 332:243-247.
69. Zelkha S.A., Freilich R.W., Amar S. Periodontal innate immune mechanisms relevant to atherosclerosis and obesity. Periodontol 2000 2010, 54:207-221.
70. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007, 117:175-184.
71. Prieur X., Mok C.Y., Velagapudi V.R., Nunez V., Fuentes L., Montaner D., et al. Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2/M1 polarization in obese mice. Diabetes 2011, 60:797-809.
72. Cinti S., Mitchell G., Barbatelli G., Murano I., Ceresi E., Faloia E., et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005, 46:2347-2355.
73. Nguyen M.T., Favelyukis S., Nguyen A.K., Reichart D., Scott P.A., Jenn A., et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007, 282:35279-35292.
74. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006, 116:3015-3025.
75. Vandanmagsar B., Youm Y.H., Ravussin A., Galgani J.E., Stadler K., Mynatt R.L., et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011, 17:179-188.
76. Tsukumo D.M., Carvalho-Filho M.A., Carvalheira J.B., Prada P.O., Hirabara S.M., Schenka A.A., et al. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007, 56:1986-1998.
77. Saberi M., Woods N.B., de Luca C., Schenk S., Lu J.C., Bandyopadhyay G., et al. Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab 2009, 10:419-429.
78. Cullinan M.P., Hamlet S.M., Westerman B., Palmer J.E., Faddy M.J., Seymour G.J. Acquisition and loss of Porphyromonas gingivalis, Actinobacillus actinomycetemcomitans and Prevotella intermedia over a 5-year period: effect of a triclosan/copolymer dentifrice. J Clin Periodontol 2003, 30:532-541.
79. Zappa U., Reinking-Zappa M., Graf H., Espeland M. Cell populations and episodic periodontal attachment loss in humans. J Clin Periodontol 1991, 18:508-515.
80. Li C.H., Amar S. Morphometric, histomorphometric, and microcomputed tomographic analysis of periodontal inflammatory lesions in a murine model. J Periodontol 2007, 78:1120-1128.
81. Yang Y., Liu B., Dai J., Srivastava P.K., Zammit D.J., Lefrancois L., et al. Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages. Immunity 2007, 26:215-226.
82. Slots J., Genco R.J. Black-pigmented Bacteroides species, Capnocytophaga species, and Actinobacillus actinomycetemcomitans in human periodontal disease: virulence factors in colonization, survival, and tissue destruction. J Dent Res 1984, 63:412-421.
83. Muthukuru M., Jotwani R., Cutler C.W. Oral mucosal endotoxin tolerance induction in chronic periodontitis. Infect Immun 2005, 73:687-694.
84. Tanabe S.I., Grenier D. Macrophage tolerance response to Aggregatibacter actinomycetemcomitans lipopolysaccharide induces differential regulation of tumor necrosis factor-alpha, interleukin-1 beta and matrix metalloproteinase 9 secretion. J Periodontal Res 2008, 43:372-377.
85. Robbins S.L., Kumar V., Cotran R.S. Robbins and Cotran pathologic basis of disease 2010, Saunders/Elsevier, Philadelphia, PA. 8th ed.
86. Diegelmann R.F., Evans M.C. Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci 2004, 9:283-289.
87. Guo S., Dipietro L.A. Factors affecting wound healing. J Dent Res 2010, 89:219-229.
88. Clark R.A. Fibrin and wound healing. Ann N Y Acad Sci 2001, 936:355-367.
89. Barrientos S., Stojadinovic O., Golinko M.S., Brem H., Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen 2008, 16:585-601.
90. Broughton G., Janis J.E., Attinger C.E. The basic science of wound healing. Plast Reconstr Surg 2006, 117:12S-34S.
91. Werner S., Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003, 83:835-870.
92. Artuc M., Hermes B., Steckelings U.M., Grutzkau A., Henz B.M. Mast cells and their mediators in cutaneous wound healing-active participants or innocent bystanders?. Exp Dermatol 1999, 8:1-16.
93. Adamson R. Role of macrophages in normal wound healing: an overview. J Wound Care 2009, 18:349-351.
94. Erwig L.P., Henson P.M. Immunological consequences of apoptotic cell phagocytosis. Am J Pathol 2007, 171:2-8.
95. Fadok V.A., McDonald P.P., Bratton D.L., Henson P.M. Regulation of macrophage cytokine production by phagocytosis of apoptotic and post-apoptotic cells. Biochem Soc Trans 1998, 26:653-656.
96. Sylvia C.J. The role of neutrophil apoptosis in influencing tissue repair. J Wound Care 2003, 12:13-16.
97. Keen D. A review of research examining the regulatory role of lymphocytes in normal wound healing. J Wound Care 2008, 17:218-220. 22.
98. Knighton D.R., Hunt T.K., Scheuenstuhl H., Halliday B.J., Werb Z., Banda M.J. Oxygen tension regulates the expression of angiogenesis factor by macrophages. Science 1983, 221:1283-1285.
99. LaVan F.B., Hunt T.K. Oxygen and wound healing. Clin Plast Surg 1990, 17:463-472.
100. Gill S.E., Parks W.C. Metalloproteinases and their inhibitors: regulators of wound healing. Int J Biochem Cell Biol 2008, 40:1334-1347.
101. Wynn T.A., Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 2010, 30:245-257.
102. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J Pathol 2008, 214:199-210.
103. Koh T.J., DiPietro L.A. Inflammation and wound healing: the role of the macrophage. Expert Rev Mol Med 2011, 13:e23.
104. Rodero M.P., Khosrotehrani K. Skin wound healing modulation by macrophages. Int J Clin Exp Pathol 2010, 3:643-653.
105. Deonarine K., Panelli M.C., Stashower M.E., Jin P., Smith K., Slade H.B., et al. Gene expression profiling of cutaneous wound healing. J Transl Med 2007, 5:11.
106. Lucas T., Waisman A., Ranjan R., Roes J., Krieg T., Muller W., et al. Differential roles of macrophages in diverse phases of skin repair. J Immunol 2010, 184:3964-3977.
107. Mirza R., DiPietro L.A., Koh T.J. Selective and specific macrophage ablation is detrimental to wound healing in mice. Am J Pathol 2009, 175:2454-2462.
108. Mahbub S., Deburghgraeve C.R., Kovacs E.J. Advanced age impairs macrophage polarization. J Interferon Cytokine Res 2012, 32:18-26.
109. Tidball J.G., Villalta S.A. Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol 2010, 298:R1173-R1187.
110. Le Grand F., Rudnicki M.A. Skeletal muscle satellite cells and adult myogenesis. Curr Opin Cell Biol 2007, 19:628-633.
111. Wehling M., Spencer M.J., Tidball J.G. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol 2001, 155:123-131.
112. Arnold L., Henry A., Poron F., Baba-Amer Y., van Rooijen N., Plonquet A., et al. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J Exp Med 2007, 204:1057-1069.
113. Summan M., Warren G.L., Mercer R.R., Chapman R., Hulderman T., Van Rooijen N., et al. Macrophages and skeletal muscle regeneration: a clodronate-containing liposome depletion study. Am J Physiol Regul Integr Comp Physiol 2006, 290:R1488-R1495.
114. Tidball J.G., Wehling-Henricks M. Macrophages promote muscle membrane repair and muscle fibre growth and regeneration during modified muscle loading in mice in vivo. J Physiol 2007, 578:327-336.
115. Lolmede K., Campana L., Vezzoli M., Bosurgi L., Tonlorenzi R., Clementi E., et al. Inflammatory and alternatively activated human macrophages attract vessel-associated stem cells, relying on separate HMGB1- and MMP-9-dependent pathways. J Leukoc Biol 2009, 85:779-787.
116. Torrente Y., El Fahime E., Caron N.J., Del Bo R., Belicchi M., Pisati F., et al. Tumor necrosis factor-alpha (TNF-alpha) stimulates chemotactic response in mouse myogenic cells. Cell Transplant 2003, 12:91-100.
117. Wang X., Wu H., Zhang Z., Liu S., Yang J., Chen X., et al. Effects of interleukin-6, leukemia inhibitory factor, and ciliary neurotrophic factor on the proliferation and differentiation of adult human myoblasts. Cell Mol Neurobiol 2008, 28:113-124.
118. Serrano A.L., Baeza-Raja B., Perdiguero E., Jardi M., Munoz-Canoves P. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab 2008, 7:33-44.
119. Li Y.P. TNF-alpha is a mitogen in skeletal muscle. Am J Physiol Cell Physiol 2003, 285:C370-C376.
120. Nguyen H.X., Tidball J.G. Interactions between neutrophils and macrophages promote macrophage killing of rat muscle cells in vitro. J Physiol 2003, 547:125-132.
121. Szalay K., Razga Z., Duda E. TNF inhibits myogenesis and downregulates the expression of myogenic regulatory factors myoD and myogenin. Eur J Cell Biol 1997, 74:391-398.
122. Tsujinaka T., Fujita J., Ebisui C., Yano M., Kominami E., Suzuki K., et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 1996, 97:244-249.
123. St Pierre B.A., Tidball J.G. Differential response of macrophage subpopulations to soleus muscle reloading after rat hindlimb suspension. J Appl Physiol 1994, 77:290-297.
124. Villalta S.A., Rinaldi C., Deng B., Liu G., Fedor B., Tidball J.G. Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. Hum Mol Genet 2011, 20:790-805.
125. Strle K., McCusker R.H., Tran L., King A., Johnson R.W., Freund G.G., et al. Novel activity of an anti-inflammatory cytokine: IL-10 prevents TNFalpha-induced resistance to IGF-I in myoblasts. J Neuroimmunol 2007, 188:48-55.
126. Villalta S.A., Nguyen H.X., Deng B., Gotoh T., Tidball J.G. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet 2009, 18:482-496.
127. Villalta S.A., Deng B., Rinaldi C., Wehling-Henricks M., Tidball J.G. IFN-gamma promotes muscle damage in the mdx mouse model of Duchenne muscular dystrophy by suppressing M2 macrophage activation and inhibiting muscle cell proliferation. J Immunol 2011, 187:5419-5428.
128. Kigerl K.A., Gensel J.C., Ankeny D.P., Alexander J.K., Donnelly D.J., Popovich P.G. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 2009, 29:13435-13444.
129. Rolls A., Shechter R., Schwartz M. The bright side of the glial scar in CNS repair. Nat Rev Neurosci 2009, 10:235-241.
130. Shechter R., London A., Varol C., Raposo C., Cusimano M., Yovel G., et al. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med 2009, 6:e1000113.
131. Schwartz M. "Tissue-repairing" blood-derived macrophages are essential for healing of the injured spinal cord: from skin-activated macrophages to infiltrating blood-derived cells?. Brain Behav Immun 2010, 24:1054-1057.
132. Lazarov-Spiegler O., Rapalino O., Agranov G., Schwartz M. Restricted inflammatory reaction in the CNS: a key impediment to axonal regeneration?. Mol Med Today 1998, 4:337-342.
133. Bomstein Y., Marder J.B., Vitner K., Smirnov I., Lisaey G., Butovsky O., et al. Features of skin-coincubated macrophages that promote recovery from spinal cord injury. J Neuroimmunol 2003, 142:10-16.
134. Lazarov-Spiegler O., Solomon A.S., Zeev-Brann A.B., Hirschberg D.L., Lavie V., Schwartz M. Transplantation of activated macrophages overcomes central nervous system regrowth failure. FASEB J 1996, 10:1296-1302.
135. Rapalino O., Lazarov-Spiegler O., Agranov E., Velan G.J., Yoles E., Fraidakis M., et al. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med 1998, 4:814-821.
136. Ziv Y., Avidan H., Pluchino S., Martino G., Schwartz M. Synergy between immune cells and adult neural stem/progenitor cells promotes functional recovery from spinal cord injury. Proc Natl Acad Sci USA 2006, 103:13174-13179.
137. Schwartz M., Yoles E. Immune-based therapy for spinal cord repair: autologous macrophages and beyond. J Neurotrauma 2006, 23:360-370.
138. Pesce J.T., Ramalingam T.R., Mentink-Kane M.M., Wilson M.S., El Kasmi K.C., Smith A.M., et al. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog 2009, 5:e1000371.
139. Pesce J.T., Ramalingam T.R., Wilson M.S., Mentink-Kane M.M., Thompson R.W., Cheever A.W., et al. Retnla (relmalpha/fizz1) suppresses helminth-induced Th2-type immunity. PLoS Pathog 2009, 5:e1000393.
140. Wilson M.S., Elnekave E., Mentink-Kane M.M., Hodges M.G., Pesce J.T., Ramalingam T.R., et al. IL-13Ralpha2 and IL-10 coordinately suppress airway inflammation, airway-hyperreactivity, and fibrosis in mice. J Clin Invest 2007, 117:2941-2951.
141. Anderson J.M., Jones J.A. Phenotypic dichotomies in the foreign body reaction. Biomaterials 2007, 28:5114-5120.
142. Anderson J.M., Rodriguez A., Chang D.T. Foreign body reaction to biomaterials. Semin Immunol 2008, 20:86-100.
143. Shanbhag A.S., Jacobs J.J., Glant T.T., Gilbert J.L., Black J., Galante J.O. Composition and morphology of wear debris in failed uncemented total hip replacement. J Bone Jt Surg Br 1994, 76:60-67.
144. Goodman S.B. Wear particles, periprosthetic osteolysis and the immune system. Biomaterials 2007, 28:5044-5048.
145. Ingham E., Fisher J. The role of macrophages in osteolysis of total joint replacement. Biomaterials 2005, 26:1271-1286.
146. Bi Y., Seabold J.M., Kaar S.G., Ragab A.A., Goldberg V.M., Anderson J.M., et al. Adherent endotoxin on orthopedic wear particles stimulates cytokine production and osteoclast differentiation. J Bone Miner Res 2001, 16:2082-2091.
147. Underwood R.A., Usui M.L., Zhao G., Hauch K.D., Takeno M.M., Ratner B.D., et al. Quantifying the effect of pore size and surface treatment on epidermal incorporation into percutaneously implanted sphere-templated porous biomaterials in mice. J Biomed Mater Res A 2011, 98:499-508.
148. Madden L.R., Mortisen D.J., Sussman E.M., Dupras S.K., Fugate J.A., Cuy J.L., et al. Proangiogenic scaffolds as functional templates for cardiac tissue engineering. Proc Natl Acad Sci USA 2010, 107:15211-15216.
149. Fukano Y., Usui M.L., Underwood R.A., Isenhath S., Marshall A.J., Hauch K.D., et al. Epidermal and dermal integration into sphere-templated porous poly(2-hydroxyethyl methacrylate) implants in mice. J Biomed Mater Res A 2010, 94:1172-1186.
150. Saino E., Focarete M.L., Gualandi C., Emanuele E., Cornaglia A.I., Imbriani M., et al. Effect of electrospun fiber diameter and alignment on macrophage activation and secretion of proinflammatory cytokines and chemokines. Biomacromolecules 2011, 12:1900-1911.
151. Bota P.C., Collie A.M., Puolakkainen P., Vernon R.B., Sage E.H., Ratner B.D., et al. Biomaterial topography alters healing in vivo and monocyte/macrophage activation in vitro. J Biomed Mater Res A 2010, 95:649-657.
152. Badylak S.F., Gilbert T.W. Immune response to biologic scaffold materials. Semin Immunol 2008, 20:109-116.
153. Badylak S.F. The extracellular matrix as a biologic scaffold material. Biomaterials 2007, 28:3587-3593.
154. Badylak S.F., Valentin J.E., Ravindra A.K., McCabe G.P., Stewart-Akers A.M. Macrophage phenotype as a determinant of biologic scaffold remodeling. Tissue Eng Part A 2008, 14:1835-1842.
155. Brown B.N., Londono R., Tottey S., Zhang L., Kukla K.A., Wolf M.T., et al. Macrophage phenotype as a predictor of constructive remodeling following the implantation of biologically derived surgical mesh materials. Acta Biomater 2011.
156. Brown B.N., Valentin J.E., Stewart-Akers A.M., McCabe G.P., Badylak S.F. Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component. Biomaterials 2009, 30:1482-1491.
157. Valentin J.E., Stewart-Akers A.M., Gilbert T.W., Badylak S.F. Macrophage participation in the degradation and remodeling of extracellular matrix scaffolds. Tissue Eng Part A 2009, 15:1687-1694.